v3.25.4
Licensing, Acquisitions, and Other Arrangements (Details) - Cerevel Therapeutics - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
5 Months Ended 11 Months Ended 12 Months Ended
Aug. 01, 2024
Dec. 31, 2024
Dec. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Business Combination            
Payments to Acquire Businesses, Net of Cash Acquired       $ 204 $ 17,493 $ 0
Goodwill   $ 34,956 $ 34,956 $ 35,640 34,956 $ 32,293
Emraclidine            
Business Combination            
Impairment of Intangible Assets, Indefinite-Lived (Excluding Goodwill)         $ 4,500  
Impairment, Intangible Asset, Indefinite-Lived (Excluding Goodwill), Statement of Income or Comprehensive Income [Extensible Enumeration]         Research and development  
RSUs            
Business Combination            
Granted (in shares)   300 300 600    
Pfizer License Agreement            
Business Combination            
Aggregate Amount of Commercial Milestones Payable $ 1,600          
Cerevel Therapeutics            
Business Combination            
Cash per share received by shareholders (in dollars per share) $ 45.00          
Cash consideration paid $ 8,700          
Payments to Acquire Businesses, Net of Cash Acquired 8,300          
Business Combination, Recognized Asset Acquired, Cash and Cash Equivalent 361          
Business Combination, Recognized Asset Acquired, Investment in Debt and Equity Securities, Current 382          
Business Combination, Recognized Asset Acquired, Other Asset, Current 9          
Business Combination, Recognized Asset Acquired, Property, Plant, and Equipment 25          
Business Combination, Recognized Asset Acquired, Asset, Noncurrent 121          
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Assumed In Process Research and Development 8,100          
Business Combination, Recognized Asset Acquired, Other Asset, Noncurrent 31          
Business Combination, Recognized Liability Assumed, Long-Term Debt, Current (400)          
Business Combination, Recognized Liability Assumed, Accounts Payable, Current (100)          
Business Combination, Recognized Liability Assumed, Long-Term Debt, Noncurrent (246)          
Deferred tax liabilities (1,292)          
Business Combination, Recognized Liability Assumed, Other Liability, Noncurrent (31)          
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less) 6,960          
Goodwill 1,702          
Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill 8,662          
Aggregate principal amount of debt $ 345          
Stated interest rate (as a percent) 2.50%          
Short-term borrowings $ (400)          
Business Combination, Acquiree's Earnings (Loss) since Acquisition Date, Actual   $ (4,900)        
Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized   161        
Business Combination, Acquisition-Related Cost, Expense   $ 44